Login / Signup

Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS.

Flavia Cobianchi BellisariPierpaolo PalumboCarlo MasciocchiCarmine ZoccaliAntonio BarileFrancesco Arrigoni
Published in: Journal of clinical medicine (2021)
Osteoblastoma (OB) and osteoid osteoma (OO) are benign bone-forming tumors, with nearly identical basic microscopic features. The main difference is dimension (OO has usually a nidus measuring <2 cm in diameter). In addition, OB is biologically more active than OO, with a tendency to grow in size. Historically, treatments have included surgical resection and analgesics, although invasiveness and poor tolerance have led to the current standard of care moving toward interventional radiology, where radiofrequency ablation (RFA) represents the most diffuse technique. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) has recently emerged as another innovative alternative treatment, providing tumor ablation through a needleless and ionizing radiation-free modality. In addition, this technique has the ability to guarantee a very precise and controlled increase in temperature, delivering small amounts of energy that can accurately destroy only the lesion, avoiding healthy surrounding tissues. The present review focuses on MRgFUS as the less invasive, safe, effective, and durable treatment option for the management of osteoid osteoma and osteoblastoma, including a description of technical details, indications and outcomes.
Keyphrases
  • radiofrequency ablation
  • magnetic resonance
  • healthcare
  • palliative care
  • gene expression
  • adipose tissue
  • acute coronary syndrome
  • low grade
  • combination therapy
  • optical coherence tomography
  • health insurance